{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T20:06:26Z","timestamp":1786392386814,"version":"build-2736575974"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2023,3,1]]},"abstract":"Importance<\/jats:title>Vascular risk factors are associated with cognitive decline but studies addressing individual risk factors have not demonstrated an effect of risk factor management on the preservation of cognition. Few trials have examined the effect of vascular risk factor management on function.<\/jats:p><\/jats:sec>Objective<\/jats:title>To determine if a polypill could reduce cognitive and functional decline in people with risk factors but without manifest cardiovascular disease.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>The International Polycap Study 3 (TIPS-3) was a 2 \u00d7 2 \u00d7 2 factorial randomized clinical trial. Hospital and community-based centers in 8 countries recruited and followed up participants between July 30, 2012, and September 30, 2020. A total of 5713 individuals were randomly assigned to treatment groups, and 2098 people 65 years or older at intermediate risk of cardiovascular disease completed a cognitive assessment and were included in the analyses.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Polypill (antihypertensives and a statin), aspirin, or a combination of both treatments.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Cognitive and functional assessments completed at baseline, 2 years, and study end. The primary outcome was the effect of a polypill compared with placebo and a polypill plus aspirin compared with double placebo on the composite outcome of the proportion of participants in each group who experienced a substantive decrease (&amp;gt;1.5 SD change) in cognitive or functional abilities.<\/jats:p><\/jats:sec>Results<\/jats:title>Of the 2389 study participants older than 65 years, a total of 2098 (88%; mean [SD] age, 70.1 [4.5] years; 1266 female individuals [60%]) completed the baseline and follow-up assessment. A total of 1796 participants (86%) had hypertension, and 680 participants (32%) had impaired fasting plasma glucose levels. Mean (SD) baseline systolic blood pressure was 146.1 (17.7) mm Hg, and mean (SD) low-density lipoprotein cholesterol (LDL-C) level was 124.3 (40.7) mg\/dL and decreased by 5.7 mm Hg and 24 mg\/dL, respectively, among those assigned to the polypill group. During a 5-year follow-up, there were no significant differences between treatment groups in the number of participants who experienced substantive cognitive decline (356 assigned polypill, 328 assigned placebo) or dementia (2 assigned polypill, 4 assigned placebo). Functional decline was reduced during follow-up for those assigned to polypill compared with placebo (mean [SD] country-standardized adjusted follow-up Standard Assessment of Global Everyday Activities [SAGEA] scores, 0.06 [0.03] vs 0.15 [0.03]; P<\/jats:italic>\u2009=\u2009.01) and polypill\u2009plus\u2009aspirin compared with double placebo (mean [SD] country-standardized adjusted follow-up SAGEA scores, 0.01 [0.04] vs 0.14 [0.04]; P<\/jats:italic>\u2009=\u2009.01).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this randomized clinical trial of patients 65 years or older with vascular risk factors, a polypill, with or without aspirin, was not associated with reduced cognitive outcomes but was associated with reduced functional decline.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaneurol.2022.5088","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T16:33:50Z","timestamp":1675096430000},"page":"251","source":"Crossref","is-referenced-by-count":16,"title":["Effects of a Polypill, Aspirin, and the Combination of Both on Cognitive and Functional Outcomes"],"prefix":"10.1001","volume":"80","author":[{"given":"Jacqueline J.","family":"Bosch","sequence":"first","affiliation":[{"name":"Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada"},{"name":"School of Rehabilitation Sciences, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"HRB-Clinical Research Facility, National University Ireland, Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Gao","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Joseph","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prem","family":"Pais","sequence":"additional","affiliation":[{"name":"St John\u2019s Medical College, Bangalore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Xavier","sequence":"additional","affiliation":[{"name":"St John\u2019s Medical College, Bangalore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Dans","sequence":"additional","affiliation":[{"name":"University of the Philippines, Manila, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio","family":"Lopez Jaramillo","sequence":"additional","affiliation":[{"name":"Masira Research Institute FOSCAL, Medical School, Universidad de Santander, Bucaramanga, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Yusuf","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"noi220090r2","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3390\/geriatrics5040084","article-title":"Global cognitive impairment prevalence and incidence in community dwelling older adults: a systematic review.","volume":"5","author":"Pais","year":"2020","journal-title":"Geriatrics (Basel)"},{"issue":"7","key":"noi220090r3","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.010641","article-title":"Cardiovascular and lifestyle risk factors and cognitive function in patients with stable coronary heart disease.","volume":"8","author":"Stewart","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"noi220090r4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1161\/HYPERTENSIONAHA.120.14993","article-title":"Blood pressure and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 209 prospective studies.","volume":"76","author":"Ou","year":"2020","journal-title":"Hypertension"},{"issue":"1","key":"noi220090r5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13195-020-00658-7","article-title":"The contribution of vascular risk factors in neurodegenerative disorders: from mild cognitive impairment to Alzheimer disease.","volume":"12","author":"Cheng","year":"2020","journal-title":"Alzheimers Res Ther"},{"issue":"19","key":"noi220090r6","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1001\/jama.2020.4249","article-title":"Association of blood pressure lowering with incident dementia or cognitive impairment: a systematic review and meta-analysis.","volume":"323","author":"Hughes","year":"2020","journal-title":"JAMA"},{"issue":"16","key":"noi220090r7","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1056\/NEJMoa1800722","article-title":"Effect of aspirin on disability-free survival in the healthy elderly.","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"noi220090r8","article-title":"Statins for the prevention of dementia.","author":"McGuinness","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"13","key":"noi220090r9","doi-asserted-by":"publisher","first-page":"e1435","DOI":"10.1212\/WNL.0000000000007174","article-title":"Effects of blood pressure and lipid lowering on cognition: results from the HOPE-3 study.","volume":"92","author":"Bosch","year":"2019","journal-title":"Neurology"},{"key":"noi220090r10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ahj.2018.07.012","article-title":"The International Polycap Study-3 (Trends Pharmacol Sci-3): design, baseline characteristics, and challenges in conduct.","volume":"206","author":"Joseph","year":"2018","journal-title":"Am Heart J"},{"issue":"3","key":"noi220090r11","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1056\/NEJMoa2028220","article-title":"Polypill with or without aspirin in persons without cardiovascular disease.","volume":"384","author":"Yusuf","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"noi220090r12","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1136\/heartjnl-2017-311609","article-title":"Prognostic validation of a non-laboratory and a laboratory based cardiovascular disease risk score in multiple regions of the world.","volume":"104","author":"Joseph","year":"2018","journal-title":"Heart"},{"issue":"5","key":"noi220090r13","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1093\/eurheartj\/ehq448","article-title":"Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score.","volume":"32","author":"McGorrian","year":"2011","journal-title":"Eur Heart J"},{"issue":"4","key":"noi220090r14","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/jgs.2005.53.issue-4","article-title":"The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"noi220090r15","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.3233\/JAD-160248","article-title":"Measurement error, reliability, and minimum detectable change in the Mini-Mental State Examination, Montreal Cognitive Assessment, and Color Trails Test among community-living middle-aged and older adults.","volume":"53","author":"Feeney","year":"2016","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"noi220090r16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.acn.2007.11.005","article-title":"Trail Making Test errors in normal aging, mild cognitive impairment, and dementia.","volume":"23","author":"Ashendorf","year":"2008","journal-title":"Arch Clin Neuropsychol"},{"issue":"4","key":"noi220090r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2022.106329","article-title":"Functional abilities of an international poststroke population: Standard Assessment of Global Everyday Activities (SAGEA) scale.","volume":"31","author":"Bosch","year":"2022","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"4","key":"noi220090r18","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.bja.2021.05.037","article-title":"Standardized Assessment of Global Activities in the Elderly scale in adult cardiac surgery patients.","volume":"127","author":"Spence","year":"2021","journal-title":"Br J Anaesth"},{"issue":"3","key":"noi220090r19","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3233\/JAD-161042","article-title":"Cross-cultural applicability of the Montreal Cognitive Assessment (MoCA): a systematic review.","volume":"58","author":"O\u2019Driscoll","year":"2017","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"noi220090r20","doi-asserted-by":"publisher","first-page":"e1521","DOI":"10.1210\/clinem\/dgab022","article-title":"The relationship between glucose control and cognitive function in people with diabetes after a lacunar stroke.","volume":"106","author":"Cukierman-Yaffe","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"446","key":"noi220090r21","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk.","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"6","key":"noi220090r22","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1097\/HJH.0b013e3283603f53","article-title":"Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis.","volume":"31","author":"Levi Marpillat","year":"2013","journal-title":"J Hypertens"},{"issue":"25","key":"noi220090r23","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1016\/j.jacc.2021.04.075","article-title":"Effect of statin therapy on cognitive decline and incident dementia in older adults.","volume":"77","author":"Zhou","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"10059","key":"noi220090r24","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy.","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"noi220090r25","doi-asserted-by":"publisher","first-page":"901","DOI":"10.3233\/JAD-142910","article-title":"Patterns of cognitive decline prior to dementia in persons with mild cognitive impairment.","volume":"47","author":"Cloutier","year":"2015","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"noi220090r26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/ajh\/hpu131","article-title":"Does lowering blood pressure with antihypertensive therapy preserve independence in activities of daily living: a systematic review.","volume":"28","author":"Canavan","year":"2015","journal-title":"Am J Hypertens"},{"issue":"5","key":"noi220090r27","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.jstrokecerebrovasdis.2009.08.002","article-title":"Reliability of proxy respondents for patients with stroke: a systematic review.","volume":"19","author":"Oczkowski","year":"2010","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"noi220090r1","unstructured":"Centers for Disease Control and Prevention. Subjective cognitive decline\u2014a public health issue. Accessed August 12, 2021. https:\/\/www.cdc.gov\/aging\/aginginfo\/subjective-cognitive-decline-brief.html"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2800416\/jamaneurology_bosch_2023_oi_220090_1677854371.45972.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T15:09:34Z","timestamp":1678720174000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2800416"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2022.5088","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,1]]}}}